Johnson is an associate professor of urology at UT Southwestern Medical Center.
A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of post-ureteroscopy health care utilization, with each 100-mm³ increase doubling event odds.
A health-economic analysis of the ASPIRE trial data found that the steerable ureteroscopic renal evacuation (SURE) procedure was linked to roughly $3464 in downstream savings per patient over 2 years compared with standard ureteroscopy, with lead investigator Brett Johnson, MD, framing this as a value-committee benchmark rather than a full cost comparison, since the analysis deliberately excludes the index procedure's incremental cost due to wide variability across payers and care settings.
